MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer

Clinical Cancer Research - Tập 24 Số 18 - Trang 4579-4587 - 2018
Maria Saigí1, Juan J. Alburquerque-Béjar1, Anne Mc Leer‐Florin2, Carolina Pereira1, Eva Pros1, Octavio A. Romero1, Núria Baixeras3, Anna Esteve‐Codina4,5, Ernest Nadal6,7, Élisabeth Brambilla2, Montse Sánchez‐Céspedes1
11Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
22Département d'Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble and Université Grenoble Alpes, Grenoble, France.
33Pathology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain.
44CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
55Universitat Pompeu Fabra (UPF), Barcelona, Spain.
66Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.
77Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.

Tóm tắt

Abstract Purpose: The blockade of immune checkpoints such as PD-L1 and PD-1 is being exploited therapeutically in several types of malignancies. Here, we aimed to understand the contribution of the genetics of lung cancer to the ability of tumor cells to escape immunosurveillance checkpoints. Experimental Design: More than 150 primary non–small cell lung cancers, including pulmonary sarcomatoid carcinomas, were tested for levels of the HLA-I complex, PD-L1, tumor-infiltrating CD8+ lymphocytes, and alterations in main lung cancer genes. Correlations were validated in cancer cell lines using appropriate treatments to activate or inhibit selected pathways. We also performed RNA sequencing to assess changes in gene expression after these treatments. Results: MET-oncogenic activation tended to associate with positive PD-L1 immunostaining, whereas STK11 mutations were correlated with negative immunostaining. In MET-altered cancer cells, MET triggered a transcriptional increase of PD-L1 that was independent of the IFNγ-mediated JAK/STAT pathway. The activation of MET also upregulated other immunosuppressive genes (PDCD1LG2 and SOCS1) and transcripts involved in angiogenesis (VEGFA and NRP1) and in cell proliferation. We also report recurrent inactivating mutations in JAK2 that co-occur with alterations in MET and STK11, which prevented the induction of immunoresponse-related genes following treatment with IFNγ. Conclusions: We show that MET activation promotes the expression of several negative checkpoint regulators of the immunoresponse, including PD-L1. In addition, we report inactivation of JAK2 in lung cancer cells that prevented the response to IFNγ. These alterations are likely to facilitate tumor growth by enabling immune tolerance and may affect the response to immune checkpoint inhibitors. Clin Cancer Res; 24(18); 4579–87. ©2018 AACR.

Từ khóa


Tài liệu tham khảo

Syn, 2017, De-novo and acquired resistance to immune checkpoint targeting, Lancet Oncol, 18, e731, 10.1016/S1470-2045(17)30607-1

Shukla, 2015, Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes, Nat Biotechnol, 33, 1152, 10.1038/nbt.3344

The Cancer Genome Atlas Network, 2015, Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, 576, 10.1038/nature14129

Pereira, 2017, Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition, Clin Cancer Res, 23, 3203, 10.1158/1078-0432.CCR-16-1946-T

Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011

Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774

Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, 16, 257, 10.1016/S1470-2045(15)70054-9

Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348

Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N Engl J Med, 375, 819, 10.1056/NEJMoa1604958

Shin, 2017, Primary resistance to PD-1 blockade mediated by JAK1/2 mutations, Cancer Discov, 7, 188, 10.1158/2159-8290.CD-16-1223

Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X

Hui, 2017, Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase I trial, Ann Oncol, 1, 874, 10.1093/annonc/mdx008

Akbay, 2013, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, Cancer Discov, 3, 1355, 10.1158/2159-8290.CD-13-0310

Ota, 2015, Induction of PD-L1 Expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer, Clin Cancer Res, 21, 4014, 10.1158/1078-0432.CCR-15-0016

Rangachari, 2017, Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and PD-L1 expression in lung adenocarcinoma, J Thorac Oncol, 12, 878, 10.1016/j.jtho.2016.12.026

Dong, 2017, Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma, Clin Cancer Res, 23, 3012, 10.1158/1078-0432.CCR-16-2554

Gainor, 2016, EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis, Clin Cancer Res, 22, 4585, 10.1158/1078-0432.CCR-15-3101

Bonastre, 2015, PARD3 Inactivation in lung squamous cell carcinomas impairs STAT3 and promotes malignant invasion, Cancer Res, 75, 1287, 10.1158/0008-5472.CAN-14-2444

Conde, 2006, Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling, Clin Cancer Res, 12, 710, 10.1158/1078-0432.CCR-05-1362

Pros, 2013, Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer, Int J Cancer, 133, 898, 10.1002/ijc.28090

Saigi, 2018, Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer, Clin Transl Oncol, 20, 881, 10.1007/s12094-017-1799-7

Loke, 2003, PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells, Proc Natl Acad Sci U S A, 100, 5336, 10.1073/pnas.0931259100

Ma, 2005, Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer, Cancer Res, 65, 1479, 10.1158/0008-5472.CAN-04-2650

Frampton, 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors, Cancer Discov, 5, 850, 10.1158/2159-8290.CD-15-0285

Li, 2016, Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity, Nat Commun, 7, 12632, 10.1038/ncomms12632

Gimenez-Xavier, 2017, Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells, Mol Cancer Ther, 16, 1366, 10.1158/1535-7163.MCT-17-0104

Lastwika, 2016, Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer, Cancer Res, 76, 227, 10.1158/0008-5472.CAN-14-3362

Rhodes, 2008, Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity, Cancer Res, 68, 2366, 10.1158/0008-5472.CAN-07-5783

Platanias, 2005, Mechanisms of type-I- and type-II-interferon-mediated signalling, Nat Rev Immunol, 5, 375, 10.1038/nri1604

Lin, 2009, Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction, Org Lett, 11, 1999, 10.1021/ol900350k

Shin, 2016, Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status, Ann Surg Oncol, 23, 694, 10.1245/s10434-015-4903-7

Demuth, 2017, Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatment, Oncotarget, 8, 68221, 10.18632/oncotarget.19920

Sabari, 2017, PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC), J Clin Oncol, 35, 10.1200/JCO.2017.35.15_suppl.8512

Koyama, 2016, STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment, Cancer Res, 76, 999, 10.1158/0008-5472.CAN-15-1439

Thông tin
Thông tin xuất bản

Clinical Cancer Research

Tập 24 Số 18

4579-4587

Thông tin tác giả